HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

BIBP 3226

a selective non-peptide neuropeptide Y Y1 receptor antagonist; structure given in first source; BIBP-3435 is the S-enantiomer
Also Known As:
BIBP 3435; BIBP-3226; BIBP-3435; BIBP3226; N2-(diphenylacetyl)-N-((4-hydroxyphenyl)methyl)argininamide
Networked: 33 relevant articles (0 outcomes, 7 trials/studies)

Bio-Agent Context: Research Results

Experts

1. Kuwert, Torsten: 2 articles (03/2017 - 04/2015)
2. Maschauer, Simone: 2 articles (03/2017 - 04/2015)
3. Prante, Olaf: 2 articles (03/2017 - 04/2015)
4. Beck-Sickinger, Annette G: 2 articles (04/2015 - 02/2007)
5. Dandekar, Manoj P: 2 articles (08/2009 - 05/2009)
6. Kokare, Dadasaheb M: 2 articles (08/2009 - 05/2009)
7. Subhedar, Nishikant K: 2 articles (08/2009 - 05/2009)
8. Chen, Junzhe: 1 article (01/2022)
9. Huang, Xiao-Ru: 1 article (01/2022)
10. Lan, Hui-Yao: 1 article (01/2022)

Related Diseases

1. Neoplasms (Cancer)
2. Seizures (Absence Seizure)
01/01/2000 - "Similarly, kainate seizures were reduced by N[-2-(diphenylacetyl)-N-[(4-hydroxyphenyl)methyl-D-arginamide++ +] (BIBP 3226), a NPY Y(1) receptor antagonist. "
02/01/1998 - "Intrahippocampal administration of 10 microg BIBP3226 (N2- (diphenylacetyl)-N-[(4-hydroxyphenyl)methyl]D-arginamide), a non-peptide selective antagonist at the NPY Y1 receptors, increased threefold on average (P < 0.01) the time to onset of seizures and reduced the number of seizures and the total time in seizures three- and fourfold, respectively (P < 0.01). "
08/01/2015 - "While BIBP3226 significantly attenuated the pilocarpine-induced seizures, neither of the highly selective NPY1 receptor ligands altered the seizure severity. "
02/01/2007 - "A dual in vivo approach was used: the cumulative duration of seizures was quantified in adult male GAERS in 90-min electroencephalogram recordings following intracerebroventricular (i.c.v.) injection of: (i) subtype-selective agonists of Y1 ([Leu31Pro34]NPY, 2.5 nmol), Y2 (Ac[Leu(28,31)]NPY24-36, 3 nmol), Y5 receptors [hPP1(-17),Ala31,Aib32]NPY, 4 nmol), NPY (3 nmol) or vehicle; and following (ii) i.c.v. injection of antagonists of Y1 (BIBP3226, 20 nmol), Y2 (BIIE0246, 20 nmol) and Y5 (NPY5RA972, 20 nmol) receptors or vehicle, followed by NPY (3 nmol). "
08/01/2015 - "In this study, the controversial role of NPY1 receptors in epilepsy was reassessed by testing two highly selective NPY1 receptor ligands and a mixed NPY1/NPFF receptor antagonist BIBP3226 in a rat model for limbic seizures. "
3. Infarction (Infarctions)
4. Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome)
5. Hyperalgesia

Related Drugs and Biologics

1. Neuropeptide Y
2. Peptides (Polypeptides)
3. Leu(31)-Pro(34)- neuropeptide Y (NY-LP)
4. Neuropeptides
5. Morphine (MS Contin)
6. Ligands
7. Glycopeptides
8. Daunorubicin (Cerubidine)
9. neuropeptide Y (3-36)
10. neuropeptide FF receptor

Related Therapies and Procedures

1. Injections